BioSpace News Archive

At Historic Event to Celebrate Board Chair Kenneth G. Langone, a Surprise Announcement Honors Dr. Robert I. Grossman at NYU Langone Health’s Annual Violet Ball

American Gene Technologies announced it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully submitted its Investigational New Drug application to the Food & Drug Administration to begin a Phase 1 clinical trial for its genetically modified autologous cell therapy for HIV.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended September 30, 2019 and provided a corporate update.

Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced financial results and business highlights for the quarter ended September 30, 2019,

Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that management will participate in three upcoming conferences in November:

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the third quarter ended September 30, 2019.

Y-mAbs Therapeutics, Inc. announced that it will report its third quarter 2019 financial and operating results on Wednesday, November 13, 2019, after the close of the U.S. financial markets.

MRI Interventions, Inc. (NYSE American: MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and gene therapy, today announced that it will release financial results for its 2019 third quarter, which ended September 30, 2019, on Tuesday, November 12, 2019 after the market close

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Tuesday, November 12, 2019 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of 2019 as well as provide an update on business developments and activities.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its third quarter 2019 financial results and corporate highlights.